Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches
暂无分享,去创建一个
Yuichi Sugiyama | Aleksandra Galetin | Jan Snoeys | Pär Matsson | Y. Sugiyama | Shiew-Mei Huang | K. Brouwer | X. Chu | A. Galetin | D. Tatosian | J. Unadkat | N. Parrott | J. Snoeys | S. Nagar | P. Matsson | Xiaoyan Chu | Jashvant D. Unadkat | Yingying Guo | V. Hsu | Pradeep Sharma | Pradeep Sharma | Shiew‐Mei Huang | Vicky Hsu | Swati Nagar | Yingying Guo | Neil J. Parrott | Kim L.R. Brouwer | Daniel Tatosian | Vicky Hsu
[1] Li Wang,et al. Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics , 2016, Drug Metabolism and Disposition.
[2] I. Anderson. Understanding the processes , 2020 .
[3] S. L. Goss,et al. Effect of Ritonavir on 99mTechnetium–Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs , 2013, CPT: pharmacometrics & systems pharmacology.
[4] K. Brouwer,et al. Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in Rat Sandwich-Cultured Hepatocytes Compared with Liver Tissue , 2013, Drug Metabolism and Disposition.
[5] T. Maurer,et al. Toward a Unified Model of Passive Drug Permeation II: The Physiochemical Determinants of Unbound Tissue Distribution with Applications to the Design of Hepatoselective Glucokinase Activators , 2014, Drug Metabolism and Disposition.
[6] S. Doblas,et al. Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis , 2017, European Radiology.
[7] Malcolm Rowland,et al. Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.
[8] Y. Sugiyama,et al. Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG‐CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism , 2013, Clinical pharmacology and therapeutics.
[9] Kazuya Maeda,et al. PET Imaging–Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me , 2012, The Journal of Nuclear Medicine.
[10] K Rowland-Yeo,et al. Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[11] J. Manro,et al. Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein , 2014, Drug Metabolism and Disposition.
[12] X. Chu,et al. Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development , 2014, Drug Metabolism and Disposition.
[13] J. Huwyler,et al. Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations , 2017, Drug Metabolism and Disposition.
[14] L. Di,et al. Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes , 2017, Drug Metabolism and Disposition.
[15] M. Danhof,et al. Prediction of human CNS pharmacokinetics using a physiologically‐based pharmacokinetic modeling approach , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[16] Neil Woodhouse,et al. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition , 2013, NMR in biomedicine.
[17] M. Jamei,et al. A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine , 2013, Clinical Pharmacokinetics.
[18] Jashvant D Unadkat,et al. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the Model for Passive Placental Permeability Drugs , 2017, Drug Metabolism and Disposition.
[19] Nikolaos Tsamandouras,et al. Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk , 2014, Pharmaceutical Research.
[20] W. Löscher,et al. Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood–Brain Barrier , 2016, Clinical pharmacology and therapeutics.
[21] C. Battista,et al. Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters , 2017, Clinical pharmacology and therapeutics.
[22] Yingying Guo,et al. Ethnic Variability in the Expression of Hepatic Drug Transporters: Absolute Quantification by an Optimized Targeted Quantitative Proteomic Approach , 2015, Drug Metabolism and Disposition.
[23] M. Hann,et al. Direct Measurement of Intracellular Compound Concentration by RapidFire Mass Spectrometry Offers Insights into Cell Permeability , 2016, Journal of biomolecular screening.
[24] T. Lavé,et al. A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.
[25] J. Huwyler,et al. Current In Vitro Methods to Determine Hepatic Kpuu: A Comparison of Their Usefulness and Limitations. , 2017, Journal of pharmaceutical sciences.
[26] P. Artursson,et al. A High-Throughput Cell-Based Method to Predict the Unbound Drug Fraction in the Brain , 2014, Journal of medicinal chemistry.
[27] P. Lamy. Drug Disposition and Pharmacokinetics , 1977 .
[28] Yasuyoshi Watanabe,et al. Evaluation of Breast Cancer Resistance Protein Function in Hepatobiliary and Renal Excretion Using PET with 11C-SC-62807 , 2013, The Journal of Nuclear Medicine.
[29] M. Varma,et al. Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters , 2017, Clinical pharmacology and therapeutics.
[30] P. Artursson,et al. Intracellular drug bioavailability: a new predictor of system dependent drug disposition , 2017, Scientific Reports.
[31] A. McIntosh,et al. FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein. , 2016, Biochemistry.
[32] D. Mankoff,et al. Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.
[33] J. Wiśniewski,et al. Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes. , 2017, Molecular pharmaceutics.
[34] Kazuya Maeda,et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.
[35] Yuichi Sugiyama,et al. Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [11C]Metformin in Mouse , 2015, Pharmaceutical Research.
[36] O. Langer. Use of PET Imaging to Evaluate Transporter‐Mediated Drug‐Drug Interactions , 2016, Journal of clinical pharmacology.
[37] Maria M. Posada,et al. Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib , 2017, Clinical and translational science.
[38] C. Vanhove,et al. Synthesis, in vitro and in vivo small-animal SPECT evaluation of novel technetium labeled bile acid analogues to study (altered) hepatic transporter function. , 2016, Nuclear medicine and biology.
[39] K. Giacomini,et al. The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin , 2016, Clinical Pharmacokinetics.
[40] D. Tibboel,et al. Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics , 2015, Clinical Pharmacokinetics.
[41] Amin Rostami‐Hodjegan,et al. Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence , 2017, Clinical pharmacology and therapeutics.
[42] Ming-Rong Zhang,et al. Possible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride, a Dopamine D2 Receptor Antagonist. , 2017, Journal of pharmaceutical sciences.
[43] Y. Sugiyama,et al. Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver , 2013, Clinical pharmacology and therapeutics.
[44] Aleksandra Galetin,et al. Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[45] Yurong Lai,et al. Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs* , 2004, Journal of Biological Chemistry.
[46] Shiew-Mei Huang,et al. Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction. , 2017, Journal of pharmaceutical sciences.
[47] M Jamei,et al. ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans , 2013, Clinical pharmacology and therapeutics.
[48] J. G. Kenna,et al. In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.
[49] A. Galetin,et al. Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[50] Drugs interacting with organic anion transporter-1 affect uptake of Tc-99m-mercaptoacetyl-triglycine (MAG3) in the human kidney: therapeutic drug interaction in Tc-99m-MAG3 diagnosis of renal function and possible application of Tc-99m-MAG3 for drug development. , 2013, Nuclear medicine and biology.
[51] S. Jakobsen,et al. Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans , 2017, Clinical pharmacology and therapeutics.
[52] Peter Lundberg,et al. Physiologically Realistic and Validated Mathematical Liver Model Revels Hepatobiliary Transfer Rates for Gd-EOB-DTPA Using Human DCE-MRI Data , 2014, PloS one.
[53] Leon Aarons,et al. Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach , 2014, Pharmaceutical Research.
[54] J. Unadkat,et al. Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides , 2018, Drug Metabolism and Disposition.
[55] J. Unadkat,et al. Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model , 2016, Clinical pharmacology and therapeutics.
[56] Michael Gertz,et al. In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. , 2017, Molecular pharmaceutics.
[57] A. Galetin,et al. In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383 , 2015, Pharmaceutical Research.
[58] J. Houston,et al. Understanding the Interplay Between Uptake and Efflux Transporters Within In Vitro Systems in Defining Hepatocellular Drug Concentrations. , 2017, Journal of pharmaceutical sciences.
[59] Yuan Chen,et al. Strategies of Drug Transporter Quantitation by LC-MS: Importance of Peptide Selection and Digestion Efficiency , 2017, The AAPS Journal.
[60] Maria M. Posada,et al. Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling , 2015, Drug Metabolism and Disposition.
[61] Lei Zhang,et al. Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations , 2014, Clinical Pharmacokinetics.
[62] Murat Cirit,et al. Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies , 2018, Scientific Reports.
[63] D. Shapiro,et al. Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage , 2016, Clinical and translational science.
[64] R. Cecchelli,et al. A Simple Method for Assessing Free Brain/Free Plasma Ratios Using an In Vitro Model of the Blood Brain Barrier , 2013, PloS one.
[65] D. Shlaes,et al. A Pharmaceutical Industry Perspective , 2004 .
[66] O. van Tellingen,et al. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. , 2015, Molecular pharmaceutics.
[67] A. Galetin,et al. Novel Methodology for the Isolation of Lysosomes and Measurement of Intralysosomal Drug Accumulation , 2017 .
[68] K. Brouwer,et al. Prediction of Hepatic Efflux Transporter-Mediated Drug Interactions: When Is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors? , 2017, Journal of pharmaceutical sciences.
[69] S. Neuhoff,et al. Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis , 2016, Drug Metabolism and Disposition.
[70] Y. Sugiyama,et al. Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologica , 2017, Journal of pharmaceutical sciences.
[71] P. Jasper,et al. Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1–Transfected Human Embryonic Kidney 293 Cells , 2016, Drug Metabolism and Disposition.
[72] Aleksandra Galetin,et al. Meta-Analysis of Expression of Hepatic Organic Anion–Transporting Polypeptide (OATP) Transporters in Cellular Systems Relative to Human Liver Tissue , 2015, Drug Metabolism and Disposition.
[73] J. Wiśniewski,et al. Comparative Proteomic Analysis of Human Liver Tissue and Isolated Hepatocytes with a Focus on Proteins Determining Drug Exposure. , 2015, Journal of proteome research.
[74] D. Mankoff,et al. Regional P‐Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission Tomography , 2010, Clinical pharmacology and therapeutics.
[75] David A Mankoff,et al. Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study , 2015, Drug Metabolism and Disposition.
[76] Elevated Basal Ganglia Glucose Metabolism in Cyclosporine Neurotoxicity: A Positron Emission Tomography Imaging Study , 2002, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[77] Per Artursson,et al. Rapid measurement of intracellular unbound drug concentrations. , 2013, Molecular pharmaceutics.
[78] F. O’Sullivan,et al. Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease , 2014, The Journal of Nuclear Medicine.
[79] Johannes Kornhuber,et al. Quantitative modeling of selective lysosomal targeting for drug design , 2008, European Biophysics Journal.
[80] K. Giacomini,et al. PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters , 2018, Clinical pharmacology and therapeutics.
[81] L. Di,et al. Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines , 2018, Drug Metabolism and Disposition.
[82] Stephen Fowler,et al. Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor , 2018, The Journal of Pharmacology and Experimental Therapeutics.
[83] N. Hosten,et al. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. , 2012, Radiology.
[84] J Snoeys,et al. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK‐guided drug development approach , 2016, Clinical pharmacology and therapeutics.
[85] I. Zineh,et al. Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5 , 2016, Clinical pharmacology and therapeutics.
[86] Yasuyoshi Watanabe,et al. Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [11C]Dehydropravastatin in Rats , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[87] A. Dahan,et al. Reversal of opioid‐induced respiratory depression by BK‐channel blocker GAL021: A pharmacokinetic‐pharmacodynamic modeling study in healthy volunteers , 2015, Clinical pharmacology and therapeutics.
[88] X. Chu,et al. Species differences in drug transporters and implications for translating preclinical findings to humans , 2013, Expert opinion on drug metabolism & toxicology.
[89] A Rostami-Hodjegan,et al. Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin , 2014, CPT: pharmacometrics & systems pharmacology.
[90] X. Chu,et al. Ontogeny of Hepatic Drug Transporters as Quantified by LC‐MS/MS Proteomics , 2016, Clinical pharmacology and therapeutics.
[91] Caroline A. Lee,et al. Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design , 2015, Drug Metabolism and Disposition.
[92] Bo Feng,et al. Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach , 2017, Drug Metabolism and Disposition.
[93] F. Schmidt. Meta-Analysis , 2008 .
[94] Yuichi Sugiyama,et al. The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model , 2018, Drug Metabolism and Disposition.
[95] L. Aarons,et al. Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach , 2014, Clinical pharmacology and therapeutics.
[96] J. Manro,et al. Utility of Oatp 1 a / 1 b-Knockout and OATP 1 B 1 / 3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution : Case Studies with Pravastatin , Atorvastatin , Simvastatin , and Carboxydichlorofluorescein s , 2013 .
[97] Shiew-Mei Huang,et al. Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP , 2017, Clinical pharmacology and therapeutics.
[98] V. Lukacova,et al. Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group , 2015, Clinical pharmacology and therapeutics.
[99] Justin C. Earp,et al. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling , 2016, Drug Metabolism and Disposition.
[100] P. Vermeersch,et al. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients , 2016, European Journal of Clinical Pharmacology.
[101] Kazuya Maeda,et al. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. , 2013, Annual review of pharmacology and toxicology.
[102] Aleksandra Galetin,et al. Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.
[103] Jan Snoeys,et al. Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling , 2017, Clinical Pharmacokinetics.
[104] Aleksandra Galetin,et al. Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs , 2011, Drug Metabolism and Disposition.
[105] Yuichi Sugiyama,et al. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[106] James O Lloyd-Smith,et al. Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. , 2014, The Journal of antimicrobial chemotherapy.
[107] T. Terasaki,et al. Blood-Brain Barrier Pharmacoproteomics-Based Reconstruction of the In Vivo Brain Distribution of P-Glycoprotein Substrates in Cynomolgus Monkeys , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[108] K. Korzekwa,et al. Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[109] N Parrott,et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.
[110] Yasuyoshi Watanabe,et al. The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan. , 2011, Molecular pharmaceutics.
[111] K. Maeda,et al. Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins , 2017, Drug Metabolism and Disposition.
[112] Jeffrey P Krise,et al. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. , 2007, Journal of pharmaceutical sciences.
[113] K. Maeda,et al. Comparison of the Predictability of Human Hepatic Clearance for Organic Anion Transporting Polypeptide Substrate Drugs Between Different In Vitro-In Vivo Extrapolation Approaches. , 2017, Journal of pharmaceutical sciences.
[114] Hugh A. Barton,et al. Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human , 2014, Drug Metabolism and Disposition.